These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 17905534

  • 21. In vitro activities of tigecycline against clinical isolates from Shanghai, China.
    Zhang YY, Zhou L, Zhu DM, Wu PC, Hu FP, Wu WH, Wang F.
    Diagn Microbiol Infect Dis; 2004 Dec; 50(4):267-81. PubMed ID: 15582300
    [Abstract] [Full Text] [Related]

  • 22. In vitro activity of tigecycline against resistant micro-organisms isolated from burn patients.
    Timurkaynak F, Arslan H, Azap OK, Senger SS, Başaran O, Karaman SO, Haberal M.
    Burns; 2008 Nov; 34(7):1033-6. PubMed ID: 18539397
    [Abstract] [Full Text] [Related]

  • 23. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
    Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ.
    Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
    [Abstract] [Full Text] [Related]

  • 24. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
    Seifert H, Dowzicky MJ.
    Chemotherapy; 2009 Feb; 55(4):241-52. PubMed ID: 19468222
    [Abstract] [Full Text] [Related]

  • 25. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers.
    Gales AC, Sader HS, Fritsche TR.
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):421-7. PubMed ID: 18068934
    [Abstract] [Full Text] [Related]

  • 26. In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
    Nagy E, Dowzicky MJ.
    Scand J Infect Dis; 2010 Apr; 42(1):33-8. PubMed ID: 19883155
    [Abstract] [Full Text] [Related]

  • 27. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
    Bradford PA, Weaver-Sands DT, Petersen PJ.
    Clin Infect Dis; 2005 Sep 01; 41 Suppl 5():S315-32. PubMed ID: 16080070
    [Abstract] [Full Text] [Related]

  • 28. Tigecycline.
    Pankey GA.
    J Antimicrob Chemother; 2005 Sep 01; 56(3):470-80. PubMed ID: 16040625
    [Abstract] [Full Text] [Related]

  • 29. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.
    Goldstein EJ, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez HT.
    Antimicrob Agents Chemother; 2006 Aug 01; 50(8):2875-9. PubMed ID: 16870792
    [Abstract] [Full Text] [Related]

  • 30. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.
    Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT.
    Antimicrob Agents Chemother; 2006 Oct 01; 50(10):3507-13. PubMed ID: 16940056
    [Abstract] [Full Text] [Related]

  • 31. [Microbiological investigation of diabetic foot infections].
    Chikviladze D, Gachechiladze Kh, Mikeladze M, Metreveli D, Avazashvili D.
    Georgian Med News; 2010 Jun 01; (183):22-6. PubMed ID: 20622271
    [Abstract] [Full Text] [Related]

  • 32. Tigecycline: in-vitro performance as a predictor of clinical efficacy.
    Hawkey P, Finch R.
    Clin Microbiol Infect; 2007 Apr 01; 13(4):354-62. PubMed ID: 17359318
    [Abstract] [Full Text] [Related]

  • 33. Antibacterial effect of NSAIDS on clinical isolates of urinary tract infection and diabetic foot infection.
    Akhter T, Baqai R, Aziz M.
    Pak J Pharm Sci; 2010 Jan 01; 23(1):108-13. PubMed ID: 20067876
    [Abstract] [Full Text] [Related]

  • 34. Antimicrobial activity of tigecycline against bacterial isolates from intensive care units in a teaching hospital in Central Saudi Arabia.
    Somily AM, Al-Khattaf AS, Kambal AM.
    Saudi Med J; 2010 Jan 01; 31(1):18-24. PubMed ID: 20062893
    [Abstract] [Full Text] [Related]

  • 35. [Diabetic foot infections. Prevalence and antibiotic sensitivity of the causative microorganisms].
    Martínez-Gómez Dde A, Ramírez-Almagro C, Campillo-Soto A, Morales-Cuenca G, Pagán-Ortiz J, Aguayo-Albasini JL.
    Enferm Infecc Microbiol Clin; 2009 Jun 01; 27(6):317-21. PubMed ID: 19237227
    [Abstract] [Full Text] [Related]

  • 36. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.
    Zhanel GG, DeCorby M, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagacé-Wiens P, Walkty A, Mulvey MR, Hoban DJ, Canadian Antimicrobial Resistance Alliance.
    Diagn Microbiol Infect Dis; 2008 Sep 01; 62(1):67-80. PubMed ID: 18513913
    [Abstract] [Full Text] [Related]

  • 37. [Clinical distribution and antimicrobial resistance analysis of 754 pathogenic bacteria in diabetic foot infection].
    Shen Q, Lin D, Zhu H, Ge S, Wu W, Pan X, Gu X, Gu X, Shen F.
    Zhonghua Yi Xue Za Zhi; 2014 Apr 01; 94(12):889-94. PubMed ID: 24854906
    [Abstract] [Full Text] [Related]

  • 38. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial.
    Rodloff AC, Leclercq R, Debbia EA, Cantón R, Oppenheim BA, Dowzicky MJ.
    Clin Microbiol Infect; 2008 Apr 01; 14(4):307-14. PubMed ID: 18261126
    [Abstract] [Full Text] [Related]

  • 39. In vitro activities of 'new' and 'conventional' antibiotics against multi-drug resistant Gram negative bacteria from patients in the intensive care unit.
    Ratnam I, Franklin C, Spelman DW.
    Pathology; 2007 Dec 01; 39(6):586-8. PubMed ID: 18027263
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent.
    Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ.
    Diagn Microbiol Infect Dis; 2005 Jul 01; 52(3):165-71. PubMed ID: 16105560
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.